287 related articles for article (PubMed ID: 22406925)
1. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.
Crane CA; Ahn BJ; Han SJ; Parsa AT
Neuro Oncol; 2012 May; 14(5):584-95. PubMed ID: 22406925
[TBL] [Abstract][Full Text] [Related]
2. Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.
Vasco C; Canazza A; Rizzo A; Mossa A; Corsini E; Silvani A; Fariselli L; Salmaggi A; Ciusani E
J Neurooncol; 2013 Dec; 115(3):353-63. PubMed ID: 24005771
[TBL] [Abstract][Full Text] [Related]
3. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
4. More on the immune privilege of glioblastoma.
Weller M
Neuro Oncol; 2012 May; 14(5):527-8. PubMed ID: 22539528
[No Abstract] [Full Text] [Related]
5. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas.
El Andaloussi A; Lesniak MS
J Neurooncol; 2007 Jun; 83(2):145-52. PubMed ID: 17216339
[TBL] [Abstract][Full Text] [Related]
6. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
7. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Sayour EJ; McLendon P; McLendon R; De Leon G; Reynolds R; Kresak J; Sampson JH; Mitchell DA
Cancer Immunol Immunother; 2015 Apr; 64(4):419-27. PubMed ID: 25555571
[TBL] [Abstract][Full Text] [Related]
8. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
[TBL] [Abstract][Full Text] [Related]
9. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
[TBL] [Abstract][Full Text] [Related]
10. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells.
Mrizak D; Martin N; Barjon C; Jimenez-Pailhes AS; Mustapha R; Niki T; Guigay J; Pancré V; de Launoit Y; Busson P; Moralès O; Delhem N
J Natl Cancer Inst; 2015 Jan; 107(1):363. PubMed ID: 25505237
[TBL] [Abstract][Full Text] [Related]
11. Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence.
Parodi A; Traverso P; Kalli F; Conteduca G; Tardito S; Curto M; Grillo F; Mastracci L; Bernardi C; Nasi G; Minaglia F; Simonato A; Carmignani G; Ferrera F; Fenoglio D; Filaci G
Oncotarget; 2016 Feb; 7(6):6424-35. PubMed ID: 26824503
[TBL] [Abstract][Full Text] [Related]
12. MiR-568 inhibits the activation and function of CD4⁺ T cells and Treg cells by targeting NFAT5.
Li W; Kong LB; Li JT; Guo ZY; Xue Q; Yang T; Meng YL; Jin BQ; Wen WH; Yang AG
Int Immunol; 2014 May; 26(5):269-81. PubMed ID: 24355664
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and mechanism of Treg infiltration in human brain tumors.
Jacobs JF; Idema AJ; Bol KF; Grotenhuis JA; de Vries IJ; Wesseling P; Adema GJ
J Neuroimmunol; 2010 Aug; 225(1-2):195-9. PubMed ID: 20537408
[TBL] [Abstract][Full Text] [Related]
14. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.
El Andaloussi A; Lesniak MS
Neuro Oncol; 2006 Jul; 8(3):234-43. PubMed ID: 16723631
[TBL] [Abstract][Full Text] [Related]
15. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
16. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.
Pellegatta S; Poliani PL; Stucchi E; Corno D; Colombo CA; Orzan F; Ravanini M; Finocchiaro G
Neuro Oncol; 2010 Apr; 12(4):377-88. PubMed ID: 20308315
[TBL] [Abstract][Full Text] [Related]
17. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment.
Cantini G; Pisati F; Mastropietro A; Frattini V; Iwakura Y; Finocchiaro G; Pellegatta S
Cancer Immunol Immunother; 2011 Dec; 60(12):1739-50. PubMed ID: 21779877
[TBL] [Abstract][Full Text] [Related]
18. Human Endothelial Cells Modulate CD4
Lim WC; Olding M; Healy E; Millar TM
Front Immunol; 2018; 9():565. PubMed ID: 29628925
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
20. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.
Wainwright DA; Sengupta S; Han Y; Lesniak MS
Neuro Oncol; 2011 Dec; 13(12):1308-23. PubMed ID: 21908444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
